



New Product

PrBortezomib for Injection SDZ

A generic equivalent to PrVelcade*

- PrBortezomib for Injection SDZ 3.5mg



STRENGTH

FORMAT

UPC

DIN

PrBortezomib for Injection SDZ 3.5mg

10ml vial

057513221743

02503352

For more information, please contact your local Sandoz Regional Manager or call our Customer Service at 1-800-361-3062.

* Registered trademark owned by its respective owner

PrBortezomib for Injection SDZ is indicated for:

As part of combination therapy for the treatment of patients with previously untreated multiple myeloma who are unsuitable for stem cell transplantation.

As part of a medically recognized combination therapy for induction treatment of patients with previously untreated multiple myeloma who are suitable for stem cell transplantation (studies were conducted with intravenous administration of bortezomib).

For the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for stem cell transplantation. Bortezomib administered subcutaneously was studied in this patient population where it was shown to be non-inferior to the intravenous administration (defined as retaining at least 60% of the intravenous administration effect) (see Product Monograph PART II, CLINICAL TRIALS).

As part of combination therapy for the treatment of patients with previously untreated mantle cell lymphoma who are unsuitable for stem cell transplantation.

For the treatment of patients with mantle cell lymphoma who have relapsed or were refractory to at least 1 prior therapy.

For more information, please contact your local Sandoz Regional Manager. Please consult Product Monograph available at sandoz.ca/en/generics or obtain a copy by calling Sandoz Medical Information at 1-800-343-8839 ext. 4636